Ruxolitinib: all 324 studies that test it
Page 4 of 4. Open to participants first (83), then studies with results posted, then the rest; newest registration first within each.
- Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With MyelofibrosisWithdrawnNCT02528877Phase 1
- Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or OlderActive, not recruitingNCT02494882Phase 1
- TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to HydroxyureaCompletedNCT02493530Phase 1
- Ruxolitinib in Combination With AutotransplantWithdrawnNCT02469974Not applicable
- CINC424A2X01B Rollover ProtocolActive, not recruitingNCT02386800Phase 4
- Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL PatientsCompletedNCT02253277Phase 1
- JAK-inhibition in Recurrent Classical Hodgkin LymphomaCompletedNCT02164500Phase 2
- Ruxolitinib Phosphate in Reducing Fatigue in Patients With Chronic Lymphocytic LeukemiaActive, not recruitingNCT02131584Phase 2
- Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AMLCompletedNCT02076191Phase 1/2
- Study of Ruxolitinib in the Treatment of Cachexia in Patients With Tumor-Associated Chronic Wasting Diseases.TerminatedNCT02072057Phase 2
- Ruxolitinib in the Treatment of Chronic Lymphocytic LeukemiaCompletedNCT02015208Phase 1/2
- Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell LymphomaCompletedNCT01965119Phase 2
- Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-LeukemiaCompletedNCT01914484Phase 1/2
- Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)CompletedNCT01895842Phase 1
- A Phase II Study of Oral JAK1/JAK2 Inhibitor INC424 in Adult Patients With Relapsed/Refractory Classical Hodgkin's LymphomaCompletedNCT01877005Phase 2
- JAK2 Inhibitors RUXOLITINIB in Patients With MyelofibrosisCompletedNCT01795677Phase 2
- Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative NeoplasmCompletedNCT01787487Phase 2
- Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase InhibitorsTerminatedNCT01751425Phase 1
- A Study to Find the Maximum Tolerated Dose of the Experimental Combination of the Drugs INC424 and BKM120 in Patients With Primary or Secondary MyelofibrosisTerminatedNCT01730248Phase 1
- Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) PatientsCompletedNCT01702064Phase 1
- Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MFCompletedNCT01644110Phase 1/2
- Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosisCompletedNCT01433445Phase 1
- INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative DiseaseCompletedNCT01164163Phase 1
- Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic SyndromeActive, not recruitingNCT00044304Phase 2